Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O14960

UPID:
LECT2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O14960; B2RA90; O14565; Q52M49

BACKGROUND:
The protein Leukocyte cell-derived chemotaxin-2, with the unique identifier O14960, is crucial for the regulation of immune responses and tissue regeneration. It is characterized by its ability to attract neutrophils to inflammation sites and enhance the proliferation of chondrocytes, according to findings published in PubMed (9524238). Notably, this protein lacks metalloendopeptidase activity, distinguishing it from other proteins in its class (PubMed:27334921).

THERAPEUTIC SIGNIFICANCE:
The exploration of Leukocyte cell-derived chemotaxin-2's functions offers promising avenues for therapeutic intervention. Its dual role in modulating immune responses and promoting chondrocyte growth presents unique opportunities for the development of novel treatments for inflammatory conditions and cartilage-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.